Georgiamune, a privately held clinical-stage biotechnology company, and Verily, a precision health technology company under Alphabet, have unveiled a strategic partnership aimed at advancing innovative therapeutics for cancer patients.
The collaboration will primarily leverage Verily’s advanced molecular and real-world evidence solutions to support the development of Georgiamune’s therapeutic candidates.
The objective of the two firms is to identify predictive and outcome biomarkers for these candidates. Additionally, the partnership will strive to enhance the efficiency of clinical development by integrating data from clinical trials and real-world longitudinal data sources.
This innovative approach to clinical trials involves the integration of various data types to pinpoint the patient populations most likely to benefit from Georgiamune’s novel therapies. It also provides a comprehensive analysis of how participants respond to the therapy over time.
In the initial stages of this partnership, the focus will be on immune mapping using Verily’s Immune Profiler for GIM-122, a dual-functioning antibody currently undergoing evaluation for safety, tolerability, and antitumor activity in a phase 1/2 clinical trial. This trial is targeted at adults with advanced solid tumour malignancies who are refractory or resistant to checkpoint inhibitors.
Georgiamune will harness the Immune Profiler to assess the pharmacodynamic effects of GIM-122 and to investigate the immune responses of patients. As part of the collaboration, the two companies have plans to extend their efforts to other assets developed by Georgiamune, not only in the field of cancer but also in other therapeutic areas, such as autoimmune diseases.
Georgiamune founder and CEO Dr Samir Khleif said: “Georgiamune is a cutting-edge innovation company with groundbreaking scientific discoveries leading to first and best-in-class immune therapies for cancer and autoimmune diseases.
“Verily’s expertise in immune profiling, real-world data, and advanced analytics provides a comprehensive data profile to accelerate the development of our novel drug candidate. This partnership will allow us to focus on identifying the patient population that could potentially benefit the most from our breakthrough discoveries.”
Verily chief medical officer and product development president Amy Abernethy said: “This partnership combines Verily’s expertise in developing connected solutions that advance research and care across oncology and autoimmune diseases with Georgiamune’s innovative approach to drug development.
“We are proud to work with Georgiamune as they use novel data sources to break new ground in the fight against cancer.”
The Immune Profiler forms an integral component of Verily Numetric, which is a comprehensive suite of precision measurement solutions designed to provide deeper insights into health and disease. This suite is instrumental in generating diverse and robust datasets that serve as a valuable resource for medical research.
In addition to the Immune Profiler, the partnership will make use of Verily Viewpoint, which is a suite of tools and services dedicated to enabling data and evidence generation. These tools and services contribute to the collection and analysis of data critical for advancing medical research.
